We report a 14-year-old boy who had successfully received allogeneic BMT for chronic granulomatous disease and 3 years later was treated with donor lymphocyte infusion (DLI, 3.3 × 10 8 cells/kg) at unstable mixed chimerism in association with reduced neutrophil function. Following DLI, the patient developed transient acute hepatic GVHD, which was confirmed by liver biopsy and was manageable with cyclosporin A and prednisolone. The patient eventually attained complete chimerism with improved neutrophil function. At the time of writing (2.5 years from the DLI), the patient is doing well, free from infectious episodes and chronic GVHD. Our experience suggests that DLI could be a safe and effective strategy for dissolution of unstable mixed chimerism in BMT recipients for inherited disorders. Keywords: bone marrow transplantation; chronic granulomatous disease; donor lymphocyte infusion; mixed chimerism Donor lymphocyte infusion (DLI) is one of the commonly used treatments for relapsed leukemia, especially in BMT recipients for CML.
Donor lymphocyte infusion (DLI) is one of the commonly used treatments for relapsed leukemia, especially in BMT recipients for CML. 1 DLI has been performed in the expectation of providing a graft-versus-leukemia (GVL) effect, with the idea that host leukemic marrow cells must be completely replaced with donor grafts with the assistance of infused donor mature T cells. Chronic granulomatous disease (CGD) is an uncommon inherited disorder of dysfunctional phagocytes characterized by recurrent pyogenic infections that usually begin early in life and may be lethal in childhood. The management of CGD had previously relied on conservative medical approaches, surgical drainage of abscesses and prolonged antibiotics for treatment or prophylaxis. Recently, interferon-␥ has been introduced in an attempt to reduce the number and severity of infections.
However, none of the CGD patients was cured by this treatment, suggesting that hematopoietic stem cell transplantation or gene therapy would be required to obtain a cure. 3 In general, BMT for patients with inherited disorders is often said to result in graft rejection or unstable mixed chimerism, 4 which may be true of CGD in which lymphocyte function would be almost normal. In the dissolution of such BMT complications, DLI has been found to be effective. 5 We report here an effective DLI at unstable mixed chimerism in an allogeneic BMT recipient for X-linked CGD.
Case report

Pre-and post-BMT course
The male patient started to have repeated infections of the skin at 2 weeks of age in 1981. The diagnosis of CGD was made at 6 months of age by verifying defective neutrophil function using nitroblue tetrazolium (NBT) slide test and flow cytometric assay of 2Ј,7Ј-dichlorofluorescein oxidation. 6 Thereafter, molecular analysis of the patient's neutrophils revealed the precise defect was in the lack of cytochrome b 558 b subunit, gp91-phox protein. 7 During his infancy and childhood, the patient continued to suffer from recurrent lymphadenitis, skin and spleen abscesses, and periostitis which were treated with trimethoprim-sulfamethoxazole, various antibiotics, granulocyte colony-stimulating factor, and surgical drainage. Allogeneic BMT was performed at 11 years old in December 1992, from a HLAand ABO-identical 15-year-old sister as the donor, who was healthy with normal neutrophil function. At the time of BMT, the patient was malnourished, short (127.5 cm, Ϫ2.3 s.d.) and weighed only 24 kg (Ϫ1.6 s.d.) because of frequent infectious episodes. The conditioning regimen consisted of BU (4 mg/kg administered daily over 4 successive days) and CY (50 mg/kg daily for 4 days). He received 4 × 10 8 /kg nucleated bone marrow cells. As prophylaxis against GVHD, methotrexate was given 15 mg/m 2 on day 1, 10 mg/m 2 on days 3 and 6, and cyclosporin A (CsA) was administered intravenously from days Ϫ1 to 16, and thereafter for 9 months orally. Evidence of engraftment was obtained on day 16 by a peripheral leukocyte count over 1 × 10 9 /l, and no further transfusion was required. The post-BMT course was uneventful without acute GVHD and 1-2 months later the NBT score and superoxide producing function improved remarkably, in association with the dominance of the donor karyotype (91.7%) in the bone marrow cells. The patient did not have episodes of severe infections nor delayed GVHD for almost 2 years under stable mixed chimerism, as shown in Table 1 . However, at around 26 months post BMT, the recipient karyotype started to dominate in the bone marrow, which was associated with reduced neutrophil function as revealed by low NBT scores, indicating possible future rejection.
DLI
At 32 months from BMT, we attempted to apply DLI therapy for the purpose of suppressing the host marrow cells and reconstructing complete chimerism. Collections of peripheral blood mononuclear cells from the original donor were without priming using CS-3000 apheresis system (Baxter, Deerfield, IL, USA) for 2 days. The collected lym- 
Clinical course following DLI
The patient did not show any signs of disease or GVHD for about a month. Four weeks later he complained of thirst and sore throat, and serum transaminases were found to be slightly elevated. At 34 months from the BMT and 10 weeks from the DLI, serum GPT was elevated over 500 IU/l (Table 1) . Hepatic GVHD was confirmed by percutaneous liver biopsy, which revealed microscopically degeneration of bile capillaries and interlobular bile ducts, including anisonucleosis, hyperchromasis and eosinophilic cytoplasm. Mild inflammatory cell infiltration into the bile duct wall and epithelial layer was noted. Neither massive hepatocyte necrosis nor portal lymphocyte infiltration was present. These histopathological changes were mostly lim-ited to bile duct damage, which was compatible with the findings of GVHD. The patient was first treated with oral prednisolone (2 mg/kg per day for 12 days), however, the liver dysfunction exacerbated. We promptly switched the treatment to a combination of oral CsA (5 mg/kg per day for 8 days) and oral prednisolone (2 mg/kg per day for 8 days). The patient recovered from liver dysfunction 2 months later and thereafter has been doing well without any specific treatment, with normal results of blood examination and no signs of GVHD. Following DLI, the patient has retained complete chimeric state and normal neutrophil function as shown in Table 1 . At this time, 2.5 years from the DLI, he is doing well with 165 cm in height and 46 kg in weight, enjoying normal school life.
Discussion
In allogeneic BMT for inherited disorders, the recipients are likely to have an unstable mixed chimerism, which would predict a forthcoming graft rejection, because of the normal function of host immunity. Until recently, in cases of graft rejection after BMT, re-transplantation was the only available treatment but had the disadvantage of regimenrelated toxicity. When our CGD case at an unstable mixed chimeric state was thought to be at high risk of later graft rejection, DLI therapy was employed in place of re-transplantation. This was successfully performed, resulting in complete chimerism with only the mild complication of transient hepatic GVHD.
The effectiveness of DLI therapy was first reported in BMT recipients for CML who relapsed after BMT. 8 Thereafter, DLI has been widely used in patients with relapsed hematological malignancies, but the usefulness and disadvantages of this procedure depend on the original disease, the duration after BMT and the number of infused T cells. In a study of CML, the earlier infusion augments the frequency and severity of GVHD, suggesting that the phase of immunological reconstitution and the extent of tolerance have an influence on the safety of DLI. 9 Concerning the number of infused cells, Mackinnon et al 10 reported that only 1 × 10 7 /kg T cells were capable of inducing complete chimerism with the minimal complications of GVHD and aplasia. These analyses, however, were based on data from adult patients suffering from hematological malignancies. Thus it is unknown whether the same may also be true of inherited disorders in childhood.
In our case, a high number of T cells (2.5 × 10 8 cells/kg) was infused and hepatic GVHD occurred in 10 weeks after DLI, partly because CsA was not administered in advance for the prophylaxis of GVHD. Fortunately, GVHD was mild and transient, and well controlled with a combination of CsA and prednisolone. Since this allo-specific reaction 11 may be unavoidable in attaining complete chimerism with DLI, refined protocols are required for determining the most appropriate number of infused T cells as well as better GVHD prophylaxis, particularly in children, to perform the DLI effectively and safely. In summary, we propose that allogeneic BMT is useful for patients with CGD and if unstable mixed chimeric state occurs following BMT, DLI could be a treatment of choice to re-attain complete chimerism.
